Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DAYTRANA

Summary for Tradename: DAYTRANA

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: DAYTRANA

Clinical Trials for: DAYTRANA

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD
Status: Completed Condition: Attention Deficit Hyperactivity Disorder; INSOMNIA

Methylphenidate Study in Breast or Gastrointestinal Cancer Patients
Status: Terminated Condition: Breast Cancer; Fatigue; Gastrointestinal Cancer

A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
Status: Recruiting Condition: HIV Dementia

The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.
Status: Terminated Condition: Parkinson's Disease

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers
Status: Completed Condition: Healthy

Effect of Methylphenidate on Connectivity
Status: Withdrawn Condition: Attention Deficit Hyperactivity Disorder

Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)
Status: Completed Condition: Attention Deficit Hyperactivity Disorder

Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
Status: Recruiting Condition: Healthy; Substance-related Disorder; Mood Disorder

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
Status: Completed Condition: Alzheimer's Disease; Apathy; Dementia; Methylphenidate

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care
Status: Completed Condition: Depression; Palliative Care; Cancer; Mental Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noven Pharms Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021514Apr 6, 2006RXNo6,210,705<disabled>Y<disabled>
Noven Pharms Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021514Apr 6, 2006RXNo6,348,211<disabled>Y<disabled>
Noven Pharms Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021514Apr 6, 2006RXNo8,632,802<disabled>Y<disabled>
Noven Pharms Inc
FILM, EXTENDED RELEASE;TRANSDERMAL021514Apr 6, 2006RXYes6,210,705<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DAYTRANA

Drugname Dosage Strength RLD Submissiondate
methylphenidateTransdermal System10 mg/9 hrs, 15 mg/9 hrs, 20 mg/9 hrs and 30 mg/9 hrsDaytrana4/13/2011

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology